A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma.

@article{Nademanee2005AP1,
  title={A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma.},
  author={Auayporn P. Nademanee and Stephen B. Forman and A. Do{\~n}a Molina and Henry Hoi Tai Fung and David K. Smith and Andy Dagis and C. S. Kwok and Dave M. Yamauchi and Anne-Line Anderson and Peter Falk and Amrita Krishnan and Mark H. Kirschbaum and Neil M Kogut and Ryotaro Nakamura and Margaret G. O'donnell and Pablo Parker and Leslie L Popplewell and Vinod Pullarkat and Roberto Ram{\'i}rez Rodr{\'i}guez and Firoozeh Sahebi and Eileen A. Smith and David Snyder and Anthony Stein and Ricardo T. Spielberger and Jasmine M Zain and Christine Gifford White and Andrew A. Raubitschek},
  journal={Blood},
  year={2005},
  volume={106 8},
  pages={
          2896-902
        }
}
We conducted a phase 1/2 trial of high-dose 90Y-ibritumomab tiuxetan in combination with high-dose etoposide (VP-16) 40 to 60 mg/kg (day -4) and cyclophosphamide 100 mg/kg (day -2) followed by autologous stem cell transplantation (ASCT) in 31 patients with CD20+ non-Hodgkin lymphoma (NHL). Patients underwent dosimetry (day -21) with 5 mCi (185 MBq) 111In-ibritumomab tiuxetan following 250 mg/m2 rituximab, followed a week later by 90Y-ibritumomab tiuxetan to deliver a target dose of 1000 cGy to… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 73 CITATIONS, ESTIMATED 32% COVERAGE

The principles and applications of avidin-based nanoparticles in drug delivery and diagnosis.

  • Journal of controlled release : official journal of the Controlled Release Society
  • 2017
VIEW 1 EXCERPT
CITES METHODS

FILTER CITATIONS BY YEAR

2006
2018

CITATION STATISTICS

  • 2 Highly Influenced Citations

  • Averaged 4 Citations per year over the last 3 years

References

Publications referenced by this paper.
SHOWING 1-10 OF 30 REFERENCES

Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2003
VIEW 1 EXCERPT

Autologous stem cell transplantation (ASCT) for mantle cell lymphoma (MCL): a report of 69 patients from City of Hope (COH) and Stanford [abstract

A Molina, D Kraft, N Carter
  • Blood. 2002;100(suppl 1):182a
  • 2002

Zevalin dose-escalation followed by high-dose BEAM and autologous peripheral blood progenitor cell (PBPC) transplant in non-Hodgkin’s lymphoma: early outcome results [abstract

JN Winter, D Inwards, W Erwin
  • 2002
VIEW 1 EXCERPT

progenitor cell ( PBPC ) transplant in non - Hodgkin ’ s lymphoma : early outcome results [ abstract ]

HC Fung, SJ Forman, A Nademanee
  • 2002

Similar Papers

Loading similar papers…